Radiotherapy alone or combined with carbogen breathing for squamous cell carcinoma of the head and neck: A prospective, randomized trial

Cancer

Volumn 104, Issue 2, 2005, Pages 332-337

  Mendenhall, William M ^a,b   Morris, Christopher G ^a   Amdur, Robert J ^a   Mendenhall, Nancy P ^a   Siemann, Dietmar W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Carbogen breathing; Radiotherapy; Survival; Treatment outcomes

Indexed keywords

CARBOGEN; CARBON DIOXIDE; OXYGEN;

ADULT; ARTICLE; BREATHING; CANCER CONTROL; CANCER RADIOTHERAPY; CARBOGEN BREATHING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CLASSIFICATION; TUMOR LOCALIZATION;

CARBON DIOXIDE; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HEAD AND NECK NEOPLASMS; HUMANS; OXYGEN; RADIATION-SENSITIZING AGENTS; RESPIRATION; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 22244488361     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21146     Document Type: Article

References (22)

1. Vaupel P, Kallinowski F, Okunieff P. Bloodflow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49:6449-6465.
2. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955;9:539-549.
3. Bush RS, Jenkin RD, Allt WE, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl. 1978;37:302-306.
4. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistence in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol. 1996;6:10-21.
5. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 1996;41:31-39.
6. Kaanders JH, Pop LA, Marres HA, et al. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother Oncol. 1998;48:115-122.
7. Siemann DW. The tumor microenvironment: a double-edged sword [editorial]. Int J Radiat Oncol Biol Phys. 1998; 42:697-699.
8. Stuben G, Stuschke M, Knuhmann K, Horsman MR, Sack H. The effect of combined nicotinamide and carbogen treatments in human tumour xenografts: oxygenation and tumour control studies. Radiother Oncol. 1998;48:143-148.
9. Powell ME, Collingridge DR, Saunders MI, Hoskin PJ, Hill SA, Chaplin DJ. Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations. Radiother Oncol. 1999;50:167-171.
10. Fleming ID, Cooper JS, Hensen DE, et al., editors. AJCC cancer staging manual, 5th ed. Philadelphia: Lippincott-Raven, 1998:21-58.
11. Mendenhall WM, Riggs CE, Amdur RJ, Hinerman RW, Villaret DB. Altered fractionation and/or adjuvant chemotherapy in definitive irradiation of squamous cell carcinoma of the head and neck. Laryngoscope. 2003;113:546-551.
12. Mendenhall WM, Villaret DB, Amdur RJ, Hinerman RW, Mancuso AA. Planned neck dissection after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head Neck. 2002;24:1012-1018.
13. Taylor JMG, Mendenhall WM, Lavey RS. Dose, time, and fraction size issues for late effects in head and neck cancers. Int J Radiat Oncol Biol Phys. 1991;22:3-11.
14. SAS Institute Inc. SAS OnlineDoc(r), version 9. Cary, NC: SAS Institute Inc., 2003.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Rijpkema ME, Kaanders JH, Joosten FBM, van der Kogel AJ, Heerschap A. Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head-and-neck tumors as measured by magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2002;53:1185-1191.
17. Saunders MI, Hoskin PJ, Pigott K, et al. Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study. Radiother Oncol. 1997;45:159-166.
18. Horsman MR, Siemann DW, Chaplin DJ, Overgaard J. Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. Radiother Oncol. 1997;45:167-174.
19. Bernier J, Denekamp J, Rojas A, et al. ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Cooperative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC). Radiother Oncol. 2000;55:111-119.
20. Kaanders JH, Pop LA, Marres HA, et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;52:769-778.
21. Martinez JC, Villar A, Cabezon MA, et al. Hyperfractionated chemoradiation with carbogen breathing, with or without erythropoietin: a stepwise developed treatment schedule for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:47-53.
22. Rischin D, Peters L, Fisher R, et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol. 2005;23:79-87.